Vericel Corp (VCEL) Swings to Profit with a 250% EPS Beat in Q2 2026
As seen on the 24/7 Wall St. homepage on July 30, 2026.
Vericel swung to profitability with a 250% EPS beat and authorized its first $200 million share buyback, signaling confidence the cell therapy company has turned the corner on sustained growth. MACI cartilage repair notched a fifth straight quarter of 20%-plus revenue growth, now reaching $65.5 million, while free cash flow surged to $14.3 million from essentially flat a year ago.
Continue ReadingShow less
Vericel reported Q2 2026 earnings per share of $0.04, flipping from an estimated loss of roughly $0.03 and beating Wall Street by about 250%. Revenue came in at $77.5 million, topping estimates of $72.7 million by around 7%. The quarter marks a meaningful step for a cell therapy company that has spent several years bouncing between small profits and small losses, as the chart of the past eight quarters makes clear.
The standout driver was MACI, Vericel's cartilage repair product, which posted its fifth consecutive quarter of 20%-plus revenue growth and reached $65.5 million on its own. Free cash flow surged to $14.3 million from essentially flat a year ago, giving the balance sheet real breathing room. Management put that confidence on display by authorizing the company's first-ever $200 million share repurchase program.
Sponsored
_________________________________
What's Your Number...?
Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
The buyback authorization is the detail most worth watching going forward. A first-time repurchase program of that size signals that leadership believes the stock is undervalued and that the shift to sustained profitability is durable rather than a one-quarter event. Whether MACI can maintain its growth streak into Q3 2026 will be the next test of that conviction.
Mentioned: VCEL